Atara Biotherapeutics (ATRA) Receives a Buy from Mizuho Securities

By Carrie Williams

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Atara Biotherapeutics (ATRAResearch Report), with a price target of $62. The company’s shares closed on Friday at $39.75.

According to, Syed is a 3-star analyst with an average return of 1.1% and a 50.5% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Wave Life Sciences, and Gilead Sciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atara Biotherapeutics with a $58.67 average price target, which is a 47.6% upside from current levels. In a report issued on March 22, Canaccord Genuity also reiterated a Buy rating on the stock with a $70 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $54.45 and a one-year low of $27.85. Currently, Atara Biotherapeutics has an average volume of 466.4K.

Based on the recent corporate insider activity of 83 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Joel Marcus, a Director at ATRA sold 62,590 shares for a total of $2,257,621.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.